Parkinson’s UK Project Grants Now Open

Parkinson’s UK is a charitable organisation that provides a range of support measures and research funding to achieve its aim of finding a cure and improving the quality of life for everyone affected by Parkinson’s disease.

Project Grants offered by Parkinson’s UK aim to help tackle major Parkinson’s research challenges with groundbreaking studies that investigate complex problems.

The grants support research projects aiming to answer a single question or small group of related questions, focused on finding new and better treatments for Parkinson’s. Applications are welcomed from researchers working across all fields of Parkinson’s research.

The scheme is open to UK universities, NHS trusts, statutory social care organisations and other research institutions. Principal applicants should hold employment or honorary (if a clinical academic) contracts with the host institution that extend beyond the period of the grant. Applicants may be new to Parkinson’s research. Co-applicants and collaborators may be based at non-UK institutions and/or at pharmaceutical or biotech companies.

There is no fixed minimum or maximum value for project grants, however, grants usually fall between £100,000 and £400,000 for up to three years. Parkinson’s UK will only reimburse directly incurred research costs for awarded grants. Costs for PhD studentships can be included within project grant applications.

Application is a two-stage process: pre-proposals followed by invited full applications. Pre-proposal applications must be submitted by the deadline of 3 February 2021. Full applications must be submitted by the deadline of 28 April 2021.

More information about this research funding opportunity and the application process is available on the RESEARCHconnect funding information platform. RESEARCHconnect provides up-to-the minute content, insight and analysis on research funding news and policy. To find out more about how RESEARCHconnect can keep you in the know, and subscription fees, contact us today.